Himelstein AL et al. CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs longer interval dosing of zoledronic acid in metastatic cancer. Proc ASCO 2015;Abstract 9501.

Morgan G et al. Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment. Clin Cancer Res 2013;19(21):6030-8. Abstract

Morgan G et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomized controlled trial. Lancet 2010;376(9757):1989-99. Abstract

Raje NS et al. Advances in supportive care for multiple myeloma. J Natl Compr Canc Netw 2014;12(4):502-11. Abstract

Raje N et al. Bone marker directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: Primary analysis results of the Z-MARK study. Proc ASH 2011;Abstract 5122.

Walker RE et al. Myeloma bone disease: Pathogenesis, current treatments and future targets. Br Med Bull 2014;111(1):117-38. Abstract